Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

October 1, 2021

Study Completion Date

August 1, 2022

Conditions
Metastatic Castration-Resistant Prostate Cancer Patients
Interventions
DRUG

Irofulven

"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."

COMBINATION_PRODUCT

Prednisolone 10 mg

"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."

Trial Locations (1)

2100

Rigshospitalet, Dept. Of Oncology, Copenhagen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Smerud Medical Research International AS

OTHER

collaborator

Lantern Pharma Inc.

INDUSTRY

lead

Allarity Therapeutics

INDUSTRY

NCT03643107 - Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) | Biotech Hunter | Biotech Hunter